Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Home
About
Overview
Open Source Software
Help
History (1)
MITF is a driver oncogene and potential therapeutic target in kidney angiomyolipoma tumors through transcriptional regulation of CYR61.
See All Pages
Find People
Find Everything
Login
to
edit your profile
(add a photo, education, awards, etc.), search
student opportunities
, and
create reports
.
Edit My Profile
My Person List (
0
)
Opportunity Search
Return to Top
MITF is a driver oncogene and potential therapeutic target in kidney angiomyolipoma tumors through transcriptional regulation of CYR61.
MITF is a driver oncogene and potential therapeutic target in kidney angiomyolipoma tumors through transcriptional regulation of CYR61. Oncogene. 2021 01; 40(1):112-126.
View in:
PubMed
subject areas
Angiomyolipoma
Animals
Cell Line, Tumor
Cell Nucleus
Cell Proliferation
Cysteine-Rich Protein 61
Gene Expression Regulation, Neoplastic
Gene Knockout Techniques
Humans
Inhibitor of Differentiation Protein 2
Kidney Neoplasms
Mice
Microphthalmia-Associated Transcription Factor
Neoplasm Invasiveness
Neoplasm Transplantation
Sequence Analysis, RNA
Transcription Initiation Site
Up-Regulation
authors with profiles
Heng-Jia Liu, Ph.D.
Henry W Long, Ph.D.
Amin Nassar, M.D.
Hans R.V. Widlund, Ph.D.
Elizabeth Petri Henske, M.D.
David Joseph Kwiatkowski, M.D., Ph.D.
Krinio Giannikou, Ph.D.
Heng Du, B.M.